Today: 29 January 2026
Subscribe
Browse Category

NASDAQ:IRWD News 2 January 2026 - 5 January 2026

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

NEW YORK, Jan 5, 2026, 06:09 ET — Premarket Ironwood Pharmaceuticals shares rose about 1% in premarket trading on Monday after Citizens upgraded the gastrointestinal drugmaker, arguing that pricing pressure on Linzess has eased. Citizens analyst Jason Butler wrote that “LINZESS headwinds have passed” as the stock traded at $4.32 at 6:01 a.m. ET; Wells Fargo also lifted its price…
5 January 2026
·····
Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

Healthcare stock Ironwood jumps 27% on Linzess price cut and 2026 profit outlook

NEW YORK, Jan 4, 2026, 13:54 ET — Market closed Ironwood Pharmaceuticals shares jumped 26.7% on Friday to close at $4.27, outpacing the broader healthcare stock complex after the company laid out a sharply higher 2026 outlook tied to its Linzess constipation drug. Investing The move matters because Ironwood is trying to prove it can generate steady cash flow from…
4 January 2026
·····
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

NEW YORK, Jan 2, 2026, 14:08 ET — Regular session AbbVie shares ticked higher on Friday after Ironwood Pharmaceuticals, its partner on constipation drug Linzess, raised its 2026 outlook and said it lowered the medicine’s list price at the start of the year. The update matters because Linzess is co-developed and co-commercialized with AbbVie in the U.S., and changes in…
2 January 2026
·····

Stock Market Today

  • DBS Shares Hit Record High: Should Investors Sell or Hold?
    January 28, 2026, 11:14 PM EST. DBS Group Holdings Limited (SGX: D05) reached a 52-week high of S$59.57 on January 28, 2026. The bank's strong fundamentals, including higher net interest margins (NIMs) and growing dividends, have driven the stock to all-time highs. DBS's common equity tier one (CET1) ratio stands at 15.1%, indicating solid capital buffers. The stock trades at a last 12 months (LTM) price-to-book ratio of 2.5, above its five-year average of 1.5, signaling elevated valuations. Investors face a choice: sell now to manage portfolio risk and protect gains amid possible earnings softness or hold for steady dividends and long-term growth in wealth management. Timing market moves is challenging; historically, DBS investors benefited most from dividends rather than frequent trading.
Go toTop